CyFlow HLA-A2 Alexa Fluor 647
| 品番 | CJ927428 | ||
|---|---|---|---|
| 抗体名 | Anti-Hu HLA-A2 AF 647,BB7.2 | ||
| 包装単位 | 100 tests | ||
| 濃度 | - | ||
| 容量 | 0.5 ml | ||
| 関連製品 (アイソタイプコントロール) |
- | ||
| 反応性|交差吸着 | Human | レーザー | Red |
| 抗原 | HLA-A2 | 最大蛍光波長 | 665 nm |
| クローン | BB7.2 | 最大励起波長 | 650 nm |
| ホスト | Mouse | 標識/Format | Alexa Fluor™ 647 |
| アイソタイプ | IgG2b | 研究分野 | MHC |
| クローナリティ | monoclonal | 用途 | Flow cytometry |
Anti-Hu HLA-A2 AF 647,BB7.2
特異性
The mouse monoclonal antibody BB7.2 recognizes an epitope at the C-terminus of α-2 helix and a turn on one of the underlying β strands within the human HLA-A2 histocompatibility antigen.
抗原情報
HLA-A2 (44 kDa) is the most frequent HLA-A allele in human ethnic populations. HLA-A, together with HLA-B and HLA-C, represent human HLA class I major histocompatibility (MHC) antigens. These intrinsic membrane glycoproteins are expressed on nucleated cells and noncovalently associate with an invariant β2-microglobulin. They carry foreign determinants important for immune recognition by cytotoxic T cells, thus important for anti-viral and anti-tumor defense.
利用方法
The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 5 µl reagent / 100 µl of whole blood or 10^6 cells in a suspension. The content of a vial (0.5 ml) is sufficient for 100 tests.
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Barouch D, Davenport M, McMichael A, Reay P: A mAb against HLA‑A2 can be influenced both positively and negatively by the associated peptide. Int·Immunol. 1995·Oct; 7(10):1599‑605. <·PMID:·8562505·>
• Brenner MB, McLean J, Yang SY, van der Poel JJ, Pious D, Strominger JL: Clonal T lymphocyte recognition of the fine structure of the HLA‑A2 molecule. J·Immunol. 1985·Jul; 135(1):384‑90. <·PMID:·2582041·>
• Forero L, Zwirner NW, Fink CW, Fernández-Viña MA, Stastny P: Juvenile arthritis, HLA‑A2 and binding of DEK oncogene‑peptides. Hum·Immunol. 1998·Jul; 59(7):443‑50. <·PMID:·9684994·>
• Hogan KT, Brown SL: Localization and characterization of serologic epitopes on HLA‑A2. Hum·Immunol. 1992·Mar; 33(3):185‑92. <·PMID:·1377666·>
• Krangel MS, Taketani S, Pious D, Strominger JL: HLA‑A2 mutants immunoselected in vitro: Definition of residues contributing to an HLA‑A2‑specific serological determinant. J·Exp·Med. 1983·Jan·1; 157(1):324‑36. <·PMID:·6184441·>
• Lee L, Loftus D, Appella E, Margulies DH, Mage M: A recombinant single‑chain HLA‑A2.1 molecule, with a cis active beta‑2‑microglobulin domain, is biologically active in peptide binding and antigen presentation. Hum·Immunol. 1996·Aug; 49(1):28‑37. <·PMID:·8839773·>
• Liang B, Zhu L, Liang Z, Weng X, Lu X, Zhang C, Li H, Wu X: A simplified PCR‑SSP method for HLA‑A2 subtype in a population of Wuhan, China. Cell·Mol·Immunol. 2006·Dec; 3(6):453‑8. <·PMID:·17257499·>
• Natali PG, Nicotra MR, Bigotti A, Venturo I, Marcenaro L, Giacomini P, Russo C: Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc·Natl·Acad·Sci·USA. 1989·Sep; 86(17):6719‑23. <·PMID:·2672003·>
• Nijman HW, Houbiers JG, Vierboom MP, van der Burg SH, Drijfhout JW, D'Amaro J, Kenemans P, Melief CJ, Kast WM: Identification of peptide sequences that potentially trigger HLA‑A2.1‑restricted cytotoxic T lymphocytes. Eur·J·Immunol. 1993·Jun; 23(6):1215‑9. <·PMID:·7684681·>
• Parham P, Brodsky FM: Partial purification and some properties of BB7.2: A cytotoxic monoclonal antibody with specificity for HLA‑A2 and a variant of HLA‑A28. Hum·Immunol. 1981·Dec; 3(4):277‑99. <·PMID:·7035415·>
• Peoples GE, Goedegebuure PS, Andrews JV, Schoof DD, Eberlein TJ: HLA‑A2 presents shared tumor‑associated antigens derived from endogenous proteins in ovarian cancer. J·Immunol. 1993·Nov·15; 151(10):5481‑91. <·PMID:·8228240·>
• Pious D, Krangel MS, Dixon LL, Parham P, Strominger JL: HLA antigen structural gene mutants selected with an allospecific monoclonal antibody. Proc·Natl·Acad·Sci·USA. 1982·Dec; 79(24):7832‑6. <·PMID:·6961455·>
• Santin AD, Bellone S, Ravaggi A, Pecorelli S, Cannon MJ, Parham GP: Induction of ovarian tumor‑specific CD8+ cytotoxic T lymphocytes by acid‑eluted peptide‑pulsed autologous dendritic cells. Obstet·Gynecol. 2000·Sep; 96(3):422‑30. <·PMID:·10960637·>
• Santos-Aguado J, Barbosa JA, Biro PA, Strominger JL: Molecular characterization of serologic recognition sites in the human HLA‑A2 molecule. J·Immunol. 1988·Oct·15; 141(8):2811‑8. <·PMID:·2459229·>
• Scornik JC: HLA‑A2 epitopes recognized by alloantibodies from broadly sensitized patients. Hum·Immunol. 1987·Apr; 18(4):277‑85. <·PMID:·2437089·>
• Taketani S, Krangel MS, Pious D, Strominger JL: Structural analysis of HLA‑A2 antigen from immunoselected mutant 8.6.1: further definition of an HLA‑A2‑specific serological determinant. J·Immunol. 1983·Dec; 131(6):2935‑8. <·PMID:·6196407·>
• Verdegaal EM, Huinink DB, Hoogstraten C, Marijnissen AK, Gorsira MB, Claas FH, Osanto S: Isolation of broadly reactive, tumor‑specific, HLA Class‑I restricted CTL from blood lymphocytes of a breast cancer patient. Hum·Immunol. 1999·Dec; 60(12):1195‑206. <·PMID:·10626733·>
Available Safety Data Sheets
CyFlow™ monoclonal antibodies SDS CA EN